Consolidated Statements of Cash Flows (unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net loss	$ (2,685)	$ (2,560)
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustment to gain on sale of Portamedic and subsidiary	150	0
Depreciation and amortization	360	646
Amortization of deferred financing fees	83	0
Provision for bad debt expense	(30)	26
Share-based compensation expense	77	235
Impairment of long-lived assets and loss on disposal of fixed assets	0	123
Change in assets and liabilities:
Accounts receivable	(672)	(1,742)
Inventories	(81)	(102)
Other assets	(229)	(502)
Accounts payable, accrued expenses and other liabilities	1,292	720
Net cash used in operating activities	(1,735)	(3,156)
Cash flows from investing activities:
Capital expenditures	(327)	(311)
Proceeds from the sale of Portamedic	743	0
Net cash provided by (used in) investing activities	416	(311)
Cash flows from financing activities:
Reduction in capital lease obligations	(1)	(48)
Proceeds related to the exercise of stock options	17	0
Debt financing fees	0	(967)
Net cash provided by (used in) financing activities	16	(1,015)
Net decrease in cash and cash equivalents	(1,303)	(4,482)
Cash and cash equivalents at beginning of period	3,970	8,319
Cash and cash equivalents at end of period	2,667	3,837
Supplemental disclosure of non-cash investing activities:
Fixed assets vouchered but not paid	230	182
Fixed assets acquired by capital lease	$ 0	$ 62